Gros David-Alexandre C 4
4 · Novus Therapeutics, Inc. · Filed Sep 15, 2020
Insider Transaction Report
Form 4
Gros David-Alexandre C
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-09-11+18,278.14→ 18,278.14 totalExercise: $500.00Exp: 2020-09-11→ Series X1 Convertible Preferred Stock (18,278.14 underlying)
Footnotes (2)
- [F1]This option represents a right to purchase a total of 18,278.14 shares of the Issuer's Series X1 Convertible Preferred Stock, one quarter of which will become fully vested and exercisable on September 11, 2021, with the remaining 13,708.605 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
- [F2]Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.